Press release article from our research archive:

Protalex Inc. Announces the FDA'S Lifting of Clinicial Hold.

NEW HOPE, Pa., Sept. 12 /PRNewswire-FirstCall/ -- Protalex Inc. (OTC Bulletin Board: PRTX) announced today that the United States Food and Drug Administration ("FDA") has removed the clinical hold on its Investigational New Drug ("IND") application for their lead compound PRTX-100. "This represents a significant milestone achievement for our company," said Steven H. Kane, President and Chief Executive Officer. "We now have FDA clearance to immediately proceed with the planned Phase I safety trial in healthy volunteers. Although the pathway to healthy volunteers presented the Company with greater challenges, we believe we are now strategically in a better position to ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!